vs
Apellis Pharmaceuticals, Inc.（APLS）与CVB FINANCIAL CORP（CVBF）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是CVB FINANCIAL CORP的1.5倍（$199.9M vs $133.8M），CVB FINANCIAL CORP同比增速更快（8.4% vs -5.9%），CVB FINANCIAL CORP自由现金流更多（$217.3M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 2.8%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
CVB金融集团是一家美国银行控股公司，运营公民商业银行，主要服务加利福尼亚州市场，面向中小企业、专业机构及个人客户提供商业银行、个人银行、财富管理等多元金融服务，核心业务包含商业贷款、存款账户、资产管理等。
APLS vs CVBF — 直观对比
营收规模更大
APLS
是对方的1.5倍
$133.8M
营收增速更快
CVBF
高出14.3%
-5.9%
自由现金流更多
CVBF
多$231.6M
$-14.3M
两年增速更快
APLS
近两年复合增速
2.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $133.8M |
| 净利润 | $-59.0M | — |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 55.6% |
| 净利率 | -29.5% | — |
| 营收同比 | -5.9% | 8.4% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $0.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSCVBF
| Q4 25 | $199.9M | $133.8M | ||
| Q3 25 | $458.6M | $128.6M | ||
| Q2 25 | $178.5M | $126.4M | ||
| Q1 25 | $166.8M | $126.7M | ||
| Q4 24 | $212.5M | $123.5M | ||
| Q3 24 | $196.8M | $126.5M | ||
| Q2 24 | $199.7M | $125.3M | ||
| Q1 24 | $172.3M | $126.6M |
净利润APLSCVBF
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $52.6M | ||
| Q2 25 | $-42.2M | $50.6M | ||
| Q1 25 | $-92.2M | $51.1M | ||
| Q4 24 | $-36.4M | — | ||
| Q3 24 | $-57.4M | $51.2M | ||
| Q2 24 | $-37.7M | $50.0M | ||
| Q1 24 | $-66.4M | $48.6M |
营业利润率APLSCVBF
| Q4 25 | -25.6% | 55.6% | ||
| Q3 25 | 48.7% | 53.7% | ||
| Q2 25 | -18.6% | 54.4% | ||
| Q1 25 | -50.0% | 54.9% | ||
| Q4 24 | -12.3% | 55.1% | ||
| Q3 24 | -24.0% | 53.5% | ||
| Q2 24 | -14.7% | 54.9% | ||
| Q1 24 | -36.0% | 52.8% |
净利率APLSCVBF
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 40.9% | ||
| Q2 25 | -23.6% | 40.0% | ||
| Q1 25 | -55.3% | 40.3% | ||
| Q4 24 | -17.1% | — | ||
| Q3 24 | -29.2% | 40.5% | ||
| Q2 24 | -18.9% | 39.9% | ||
| Q1 24 | -38.5% | 38.4% |
每股收益（稀释后）APLSCVBF
| Q4 25 | $-0.40 | $0.41 | ||
| Q3 25 | $1.67 | $0.38 | ||
| Q2 25 | $-0.33 | $0.37 | ||
| Q1 25 | $-0.74 | $0.36 | ||
| Q4 24 | $-0.30 | $0.36 | ||
| Q3 24 | $-0.46 | $0.37 | ||
| Q2 24 | $-0.30 | $0.36 | ||
| Q1 24 | $-0.54 | $0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $376.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $2.3B |
| 总资产 | $1.1B | $15.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSCVBF
| Q4 25 | $466.2M | $376.4M | ||
| Q3 25 | $479.2M | $783.9M | ||
| Q2 25 | $370.0M | $738.6M | ||
| Q1 25 | $358.4M | $529.1M | ||
| Q4 24 | $411.3M | $204.7M | ||
| Q3 24 | $396.9M | $453.5M | ||
| Q2 24 | $360.1M | $844.2M | ||
| Q1 24 | $325.9M | $949.6M |
总债务APLSCVBF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $93.1M | — |
股东权益APLSCVBF
| Q4 25 | $370.1M | $2.3B | ||
| Q3 25 | $401.2M | $2.3B | ||
| Q2 25 | $156.3M | $2.2B | ||
| Q1 25 | $164.2M | $2.2B | ||
| Q4 24 | $228.5M | $2.2B | ||
| Q3 24 | $237.1M | $2.2B | ||
| Q2 24 | $264.3M | $2.1B | ||
| Q1 24 | $266.7M | $2.1B |
总资产APLSCVBF
| Q4 25 | $1.1B | $15.6B | ||
| Q3 25 | $1.1B | $15.7B | ||
| Q2 25 | $821.4M | $15.4B | ||
| Q1 25 | $807.3M | $15.3B | ||
| Q4 24 | $885.1M | $15.2B | ||
| Q3 24 | $901.9M | $15.4B | ||
| Q2 24 | $904.5M | $16.2B | ||
| Q1 24 | $831.9M | $16.5B |
负债/权益比APLSCVBF
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.35× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $221.4M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $217.3M |
| 自由现金流率自由现金流/营收 | -7.1% | 162.4% |
| 资本支出强度资本支出/营收 | 0.1% | 3.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $391.5M |
8季度趋势，按日历期对齐
经营现金流APLSCVBF
| Q4 25 | $-14.2M | $221.4M | ||
| Q3 25 | $108.5M | $81.5M | ||
| Q2 25 | $4.4M | $53.1M | ||
| Q1 25 | $-53.4M | $41.9M | ||
| Q4 24 | $19.4M | $249.8M | ||
| Q3 24 | $34.1M | $71.4M | ||
| Q2 24 | $-8.3M | $26.1M | ||
| Q1 24 | $-133.0M | $77.5M |
自由现金流APLSCVBF
| Q4 25 | $-14.3M | $217.3M | ||
| Q3 25 | $108.3M | $80.7M | ||
| Q2 25 | $4.4M | $52.3M | ||
| Q1 25 | $-53.4M | $41.2M | ||
| Q4 24 | $19.3M | $244.6M | ||
| Q3 24 | — | $70.2M | ||
| Q2 24 | $-8.4M | $24.4M | ||
| Q1 24 | $-133.3M | $77.3M |
自由现金流率APLSCVBF
| Q4 25 | -7.1% | 162.4% | ||
| Q3 25 | 23.6% | 62.8% | ||
| Q2 25 | 2.5% | 41.4% | ||
| Q1 25 | -32.0% | 32.5% | ||
| Q4 24 | 9.1% | 198.0% | ||
| Q3 24 | — | 55.5% | ||
| Q2 24 | -4.2% | 19.5% | ||
| Q1 24 | -77.3% | 61.1% |
资本支出强度APLSCVBF
| Q4 25 | 0.1% | 3.0% | ||
| Q3 25 | 0.0% | 0.7% | ||
| Q2 25 | 0.0% | 0.7% | ||
| Q1 25 | 0.0% | 0.5% | ||
| Q4 24 | 0.0% | 4.2% | ||
| Q3 24 | 0.0% | 1.0% | ||
| Q2 24 | 0.0% | 1.4% | ||
| Q1 24 | 0.2% | 0.1% |
现金转化率APLSCVBF
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 1.55× | ||
| Q2 25 | — | 1.05× | ||
| Q1 25 | — | 0.82× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.39× | ||
| Q2 24 | — | 0.52× | ||
| Q1 24 | — | 1.59× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
CVBF
暂无分部数据
